SCALEABLE CANNABINOID TREATMENT REGIMINE AND MEDICINAL FORMULATIONS
The present invention administers a cannabinoid medication to a patient followed by observing one or more physiological responses in the patient during a first period of time when treating a medical condition. The cannabinoid medication may include one or more specific types of cannabinoids at an initial dosage level. In certain instances the cannabinoid dosage level in incremented over the first period of time. The dose of a cannabinoid corresponds to a mass of one or more cannabinoid types administered to the patient over a period of time, typically over a day. The cannabinoid treatment may be combined with one or more other methods for treating cancer, such as administering a chemotherapy agent, a KRAS inhibitor, or a CTLA-4 antigen. The present invention also includes a formulation of cannabinoid medications that span one or more ranges of milligram dosages of one or more cannabinoids in a set of formulary drugs.
1 . A method for treating a medical condition, the method comprising:
administering one or more cannabinoids to a patient according to a first treatment regimen to a patient, wherein a dosage of at least one of the one or more cannabinoids are increased over a first period of time;
monitoring one or more pathological factors of the patient; and
observing a pathological event corresponding to the one or more pathological factors, wherein the observed pathological event indicates that the medical condition is improving.
2 . The method of claim 1 , further comprising maintaining administering the increased dosage of the one or more cannabinoids after the desirable pathological event has been observed.
3 .- 11 . (canceled)
18 . A formulation of matter comprising of a plurality of discrete cannabinoid formulations, wherein the plurality of discrete cannabinoid formulations change at least according to an exponential function in a series of steps, each of the discrete cannabinoid formulations formed as a dispensable unit of a plurality of dispensable units, and each of the dispensable units of the series of dispensable units including a first cannabinoid type of tetrahydrocannabinol (THC) and a second cannabinoid type of cannabidiol (CBD).
19 . The formulation of matter of claim 18 , wherein:
a weight of THC increases according to the at least exponential function and a weight of CBD decreases according to the at least exponential function in each step of the series of steps,
a first step of the series of steps that corresponds to a first dispensable unit formulation,
a second step of the series of steps that corresponds to a second dispensable unit formulation, and
a third step of the series of steps that corresponds to a third dispensable unit formulation.
20 . The formulation of matter of claim 18 wherein:
a weight of THC and weight of CBD increases according to the at least exponential function in each step of the series of steps,
a first step of the series of steps that corresponds to a first dispensable unit formulation,
a second step of the series of steps that corresponds to a second dispensable unit formulation, and
a third step of the series of steps that corresponds to a third dispensable unit formulation.
21 . The formulation of matter of claim 18 , wherein:
a weight of THC increases according to the at least exponential function in the series of steps,
a first step of the series of steps that corresponds to a first dispensable unit formulation,
a second step of the series of steps that corresponds to a second dispensable unit formulation, and
a third step of the series of steps that corresponds to a third dispensable unit formulation.
22 . The formulation of matter of claim 18 , wherein:
a weight of CBD increases according to the at least exponential function and a weight of THC increases in the series of steps,
a first step of the series of steps that corresponds to a first dispensable unit formulation,
a second step of the series of steps that corresponds to a second dispensable unit formulation, and
a third step of the series of steps that corresponds to a third dispensable unit formulation.
23 . The formulation of matter of claim 18 , wherein each of the dispensable units of the plurality of dispensable units correspond to at least one of a pill, a capsule, or a suppository.
24 . The formulation of matter of claim 18 , wherein the series of steps corresponds to:
a first step of the series of steps that corresponds to a first dispensable unit formulation,
a second step of the series of steps that corresponds to a second dispensable unit formulation, and
a third step of the series of steps that corresponds to a third dispensable unit formulation, and
the first dispensable formulation, the second dispensable formulation, and the third dispensable formulation are each contained within a type of dispensable unit, and the type of dispensable units include at least one of a pill, a capsule, or a suppository.
25 . The formulation of matter of claim 18 , wherein:
a weight of CBD increases according to the at least exponential function and a weight of THC decreases according to the at least exponential function in each step of the series of steps,
a first step of the series of steps that corresponds to a first dispensable unit formulation,
a second step of the series of steps that corresponds to a second dispensable unit formulation, and
a third step of the series of steps that corresponds to a third dispensable unit formulation.
26 . The formulation of matter of claim 18 , wherein:
a weight of CBD increases according to the at least exponential function in the series of steps,
a first step of the series of steps that corresponds to a first dispensable unit formulation,
a second step of the series of steps that corresponds to a second dispensable unit formulation, and
a third step of the series of steps that corresponds to a third dispensable unit formulation.
27 . The formulation of matter of claim 18 , wherein:
a weight of CBD increases according to the at least exponential function and a weight of THC increases in the series of steps,
a first step of the series of steps that corresponds to a first dispensable unit formulation,
a second step of the series of steps that corresponds to a second dispensable unit formulation, and
a third step of the series of steps that corresponds to a third dispensable unit formulation.
28 . The formulation of matter of claim 18 , wherein a cancer patient consumes at least some of the dispensable units of the plurality of dispensable units as a cancer treatment.